Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy

Infections are among the main complications in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy, increasing morbidity and mortality. However, no established tools exist to detect early signs of infection. Here, we develop and validate a machine learning model to predict the daily risk of febrile neutropenia (FN). We conducted a retrospective observational study using registry data from two university hospital districts in Finland. We included adult patients with newly diagnosed AML undergoing intensive chemotherapy (n = 271, 48-hour FN outcomes=540), excluding acute promyelocytic leukemia. The model used a 48-hour prediction window and 1.2 M clinical data points to generate daily FN risk estimates. We built the model using the Extreme Gradient Boosting algorithm, explained variable importance with Shapley Additive Explanations, and evaluated and validated performance using measures of discrimination, calibration, and clinical utility. We show how seven variables predict daily FN risk: white blood cell count, temperature, time since cycle start, C-reactive protein trend, absolute neutrophil count, treatment phase, and prior antibiotic treatment. We achieve an AUROC of 0.91 (95% CI, 0.89–0.93) and a calibration slope of 0.95 (95% CI, 0.73–1.16) in the development cohort’s test set (n = 55, 48-hour FN outcomes=109) and validate performance in the external cohort (n = 136, 48-hour FN outcomes=124, AUROC 0.79 (95% CI, 0.75–0.82), calibration slope 0.65 (95% CI, 0.51–0.79)). While prospective validation is warranted, this study suggests that routinely collected clinical data may be useful for daily prediction of FN and that further development of such screening tools could potentially support personalized infection prevention. Infections can be a life-threatening complication of chemotherapy in patients with acute myeloid leukemia. Here, we developed a screening tool to help physicians detect these infections early. Using registry data from two Finnish university hospital districts, we trained an AI model to predict early infection onset over the next 48 hours. The model required seven variables, including routine laboratory tests, temperature measurements, time since each chemotherapy cycle started, and information on the treatment phase and antibiotic use. Such a screening tool could potentially support more personalized supportive care. However, the results must be confirmed prospectively before clinical adoption.

Authors

Institutions

Publication Details

Journal
Communications Medicine
Published
2026-11-13
DOI
https://doi.org/10.1038/s43856-026-02001-x
Primary Topic
Neutropenia and Cancer Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy

Oscar E. Brück, Riikka Räty, Mikko A. I. Keränen, Pia Ettala et al.
1 links
Communications Medicine
Neutropenia and Cancer Infections
article

Development and validation of a machine learning model to predict the daily risk of febrile neutropenia in patients with AML undergoing chemotherapy

Oscar E. Brück, Riikka Räty, Mikko A. I. Keränen, Pia Ettala, Anna Mervaala-Muroke, Laura Toivanen
article en

Abstract

Infections are among the main complications in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy, increasing morbidity and mortality. However, no established tools exist to detect early signs of infection. Here, we develop and validate a machine learning model to predict the daily risk of febrile neutropenia (FN). We conducted a retrospective observational study using registry data from two university hospital districts in Finland. We included adult patients with newly diagnosed AML undergoing intensive chemotherapy (n = 271, 48-hour FN outcomes=540), excluding acute promyelocytic leukemia. The model used a 48-hour prediction window and 1.2 M clinical data points to generate daily FN risk estimates. We built the model using the Extreme Gradient Boosting algorithm, explained variable importance with Shapley Additive Explanations, and evaluated and validated performance using measures of discrimination, calibration, and clinical utility. We show how seven variables predict daily FN risk: white blood cell count, temperature, time since cycle start, C-reactive protein trend, absolute neutrophil count, treatment phase, and prior antibiotic treatment. We achieve an AUROC of 0.91 (95% CI, 0.89–0.93) and a calibration slope of 0.95 (95% CI, 0.73–1.16) in the development cohort’s test set (n = 55, 48-hour FN outcomes=109) and validate performance in the external cohort (n = 136, 48-hour FN outcomes=124, AUROC 0.79 (95% CI, 0.75–0.82), calibration slope 0.65 (95% CI, 0.51–0.79)). While prospective validation is warranted, this study suggests that routinely collected clinical data may be useful for daily prediction of FN and that further development of such screening tools could potentially support personalized infection prevention. Infections can be a life-threatening complication of chemotherapy in patients with acute myeloid leukemia. Here, we developed a screening tool to help physicians detect these infections early. Using registry data from two Finnish university hospital districts, we trained an AI model to predict early infection onset over the next 48 hours. The model required seven variables, including routine laboratory tests, temperature measurements, time since each chemotherapy cycle started, and information on the treatment phase and antibiotic use. Such a screening tool could potentially support more personalized supportive care. However, the results must be confirmed prospectively before clinical adoption.

Communications Medicine
University of Helsinki (FI), University of Turku (FI), Helsinki University Hospital (FI), Turku University Hospital (FI)
Blood Disease Research Foundation, Helsingin Yliopisto, Suomen Lääketieteen Säätiö, Finska Läkaresällskapet, Sigrid Juséliuksen Säätiö, Svenska Läkaresällskapet, Instrumentariumin Tiedesäätiö, Syöpäsäätiö
Good health and well-being
Neutropenia and Cancer Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon